2021
DOI: 10.1016/j.annonc.2021.08.1830
|View full text |Cite
|
Sign up to set email alerts
|

1225P The progression-free survival of the first-line EGFR-TKI is a strong prognosticator of the second-line osimertinib in non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation: A real-world study

Abstract: Background: As a third generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), osimertinib is recommended as standardized treatment for advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation after progressed on first-line EGFR-TKI. Our study aims to investigate the prognostic value of first-line EGFR-TKI on the second-line osimertinib in the real-world practice.Methods: A total of 198 NSCLC patients with EGFR-T790M between 2016 and 2020 were includ… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles